Member Info for Prion25

https://openres.ersjournals.com/content/9/2/00605-2022
Very confused with the Sprinter Results seems like Raw Data to me and annoying trolls chipping in with their off the cuff interpretations .Wait a minute why am listening to them! In response I have posted the link to the peer review reported in the ERJ open Research for all those who were dismayed reading the those results. The peer review gives greater insight from the scientists in our Synairgen team ATB

Drive appears to me to replicate the primary and secondary objectives in the Universal Trial , phenotypic characterisation
patient Stratification not too sure about endotyping but it is used in the taxonomy of COPD and Asthma . The data from Universal could be very significant to provide the heads up sngoo1 for any potential trial including Drive ?

King Charles in the German Parliament gave support to the development of the Hydrogen economy to tackle climate change and energy crisis

King Charles in the German Parliament gave support to the development of the Hydrogen economy to tackle climate change

https://isirv.org/site/index.php/component/content/article/9-events/570-7th-isirv-avg-abstract-submission
I wonder if they will present an abstract ref Host Directed Antiviral Therapeutics

Apologies if already posted
https://www.gov.uk/government/news/mhra-to-streamline-clinical-trial-approvals-in-biggest-overhaul-of-trial-regulation-in-20-years

https://www.bbc.co.uk/iplayer/live/bbcnews
Watch around 10:50 also referenced COPD SNG is still very much in the game

Back on the Oz theme very interesting article albeit 6 months old
https://endpts.com/from-australia-new-173m-research-center-strives-to-be-at-the-forefront-of-pandemic-drug-discovery/
“We need those technologies because with the existing technologies, there isn’t a way to speed up what we currently do,” she said, adding that three approaches appear promising: nucleic acid therapeutics, treatments that modulate the innate immune response, and developing cheaper and simpler-to-use antibody therapies "

Synairgen has past product success and research with Australian company Pharmaxis. Lets hope it all comes good again in Oz

Interesting
I see SAR having been delayed by MHRA in UK for a P1a trial have sought CTA application in Australia and expect approval in Q2
from the RNS
Australia offers state-of-the-art research facilities and an efficient approval process, making it an attractive location for research and development. Moreover, the country provides significant tax incentives for companies that conduct their research in Australia, allowing them to claim up to 43.5% of their eligible R&D expenditure as a cash payment. As such, Sareum has established the required local presence by setting up a legal entity in Australia

Gov are going to support Breakthrough UK Science that what we have got and that's all you need to know .GLA

"Super Science "drug research companies to get huge tax relief

MHRA reform to swift approval of drugs
Super Science small drug research companies huge tax relief

I am no expert but I believe its mostly start up tech stocks

The broker Numis is targeting a share price of 50p, down from 80p,

Why is Lemos excited what are the reasons for this optimism in this bleak environment?

Horizon might help but depends on the DUP UK in a political mess

https://www.upstreamonline.com/exclusive/shell-makes-big-oil-discovery-offshore-namibia-results-imminent/2-1-1413816

Just a reminder .The CEO of Shionogi put forward a hypothesis that their drug will prevent the development of Long Covid but will have to have proof of this .It is very frustrating that Synairgen produced unique LC data back in September and praised by Prof Chris Brightling .

"Shionogi the company says interim results of a study suggest taking the pill could lessen a patient’s chances of developing long COVID-19."

“If you kill the virus fast enough and sharp enough, the lower the probability of long COVID. That’s our hypothesis, but we need to prove that,” Teshirogi said in an interview.

Remdesivir, Evushield and Molnupiravir have been axed , Paxlovid not suitable for hospitalised patients ? Monoclonals unreliable ,what else is there in the cupboard ??